Inogen Inc 8-K

What Happened

• On April 6, 2026, Inogen, Inc. filed an 8‑K (Items 1.01, 5.02, 7.01) announcing it entered a Cooperation Agreement with Kent Lake Partners LP, Kent Lake PR LLC and Benjamin Natter, and appointed Vafa Jamali as a Class I director effective the earlier of the Company’s 2026 annual meeting or June 15, 2026. Mr. Jamali will serve until the 2027 annual meeting and has been appointed to the Audit Committee and Compliance Committee; the Board has determined he meets Nasdaq independence standards. The company also issued a press release the same day.

Key Details

• Cooperation Agreement parties: Kent Lake Partners LP, Kent Lake PR LLC, and Benjamin Natter; effective April 6, 2026.
• Investor voting/standstill terms: Investor Parties will vote their shares in line with the Board’s recommendations during the agreement term (except for “Extraordinary Transactions” and new takeover-defense proposals) and agree to customary standstill restrictions, including not acquiring more than 4.99% of Voting Securities.
• Agreement term: terminates on the earlier of (i) 30 days before the deadline for director nominations and stockholder proposals for the 2027 annual meeting, or (ii) January 11, 2027.
• Director appointment & pay: Vafa Jamali (age 56) — former CEO of ZimVie (Feb 2021–Nov 2025) and senior roles at Medtronic — will receive cash fees ($45,000 board; $10,000 Audit Committee; $5,000 Compliance Committee, prorated) and an initial RSU award with a grant-date fair value of $180,000 that vests on the earlier of one year or the day before the 2027 annual meeting, subject to continued service.

Why It Matters

• For investors, the Cooperation Agreement reduces the likelihood of immediate activist-driven proxy actions by the named Investor Parties through near-term voting support for the current Board and standstill/ownership limits. The board addition of Vafa Jamali brings an experienced medical-device and respiratory industry executive to Inogen’s governance, and his cash and equity compensation aligns his interests with shareholders during his term. The agreement is short‑term (through early 2027), so any longer‑term governance or strategic outcomes remain to be seen.